| Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration. | |
| | |
MedLine Citation:
|
PMID: 19260767 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Myocardial ischemia and cardiac dysfunction have been known to follow ischemic heart diseases (IHDs). Despite a plethora of conventional treatment options, their efficacies are associated with skepticism. Cell therapies harbor a promising potential for vascular and cardiac repair, which is corroborated by adequate preclinical evidence. The underlying objectives behind cardiac regenerative therapies subsume enhancing angiomyogenesis in the ischemic myocardium, ameliorating cellular apoptosis, regenerating the damaged myocardium, repopulating the lost resident myocardial cells (smooth muscle, cardiomyocyte, and endothelial cells), and finally, decreasing fibrosis with a consequent reduction in ventricular remodeling. Although-cell based cardiomyoplasty approaches have an immense potential, their clinical utilization is limited owing to the increased need for better candidates for cellular cardiomyoplasty, better routes of delivery, appropriate dose for efficient engraftment, and better preconditioning or genetic-modification strategies for the progenitor and stem cells. Mesenchymal stem cells (MSCs) have emerged as powerful candidates in mediating myocardial repair owing to their unique properties of multipotency, transdifferentiation, intercellular connection with the resident cardiomyocytes via connexin 43 (Cx43)-positive gap junctions in the myocardium, and most important, immunomodulation. In this review, we present an in-depth discussion on the complexities associated with stem and progenitor cell therapies, the potential of preclinical approaches involving MSCs for myocardial repair, and an account of the past milestones and ongoing MSC-based trials in humans. |
| | |
Authors:
|
Debayon Paul; Samson Mathews Samuel; Nilanjana Maulik |
Related Documents
:
|
20303947 - Heme oxygenase-1 and carbon monoxide promote neovascularization after myocardial infarc... 19246487 - The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and pr... 2933527 - Regional myocyte size in compensated right ventricular hypertrophy in the ferret. 7692167 - Effect of enalapril on intracellular resistance and conduction velocity in rat ventricu... 1401607 - Left ventricular relaxation in dilated cardiomyopathy: relation to loading conditions a... 18031507 - Variability in post-pacing intervals predicts global atrial activation pattern during t... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Antioxidants & redox signaling Volume: 11 ISSN: 1557-7716 ISO Abbreviation: Antioxid. Redox Signal. Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-12-01 Completed Date: 2010-02-18 Revised Date: 2013-06-02 |
Medline Journal Info:
|
Nlm Unique ID: 100888899 Medline TA: Antioxid Redox Signal Country: United States |
Other Details:
|
Languages: eng Pagination: 1841-55 Citation Subset: IM |
Affiliation:
|
Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health Center, Farmington, Connecticut 06030-1110, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cell Differentiation Cell Transplantation Female Heart / physiopathology* Mesenchymal Stromal Cells / cytology* Mice Mice, Inbred C57BL Myocardial Ischemia / therapy* Rats Rats, Inbred F344 Regeneration* |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Outcomes of different subgroups of smear-positive retreatment patients under RNTCP in rural West Ben...
Next Document: Single-Chain Antibodies That Target Lentiviral Vectors to MHC Class II on Antigen-Presenting Cells.